Strategic Investment Advisors MI Acquires 1,662 Shares of United Therapeutics Corporation $UTHR

Strategic Investment Advisors MI increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 20.5% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,752 shares of the biotechnology company’s stock after purchasing an additional 1,662 shares during the period. Strategic Investment Advisors MI’s holdings in United Therapeutics were worth $5,782,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Avoro Capital Advisors LLC lifted its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the last quarter. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC grew its stake in shares of United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of United Therapeutics in the fourth quarter worth about $293,418,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent research reports. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Royal Bank Of Canada increased their price objective on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $648.33.

United Therapeutics Stock Up 0.2%

Shares of UTHR stock opened at $524.70 on Thursday. The firm has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 1.75 and a beta of 0.58. The stock has a fifty day moving average of $545.45 and a 200 day moving average of $532.24. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the firm posted $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 502,833 shares of company stock worth $279,835,157 in the last 90 days. 8.60% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.